Literature DB >> 20431043

Randomized intervention studies in human polycystic kidney and liver disease.

Robert W Schrier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431043     DOI: 10.1681/ASN.2010030262

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  3 in total

1.  Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.

Authors:  Djalila Mekahli; Jean-Paul Decuypere; Eva Sammels; Kirsten Welkenhuyzen; Joost Schoeber; Marie-Pierre Audrezet; Anniek Corvelyn; Georges Dechênes; Albert C M Ong; Martijn J Wilmer; Lambertus van den Heuvel; Geert Bultynck; Jan B Parys; Ludwig Missiaen; Elena Levtchenko; Humbert De Smedt
Journal:  Pflugers Arch       Date:  2013-11-06       Impact factor: 3.657

2.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

3.  TNF-α blockade is ineffective in animal models of established polycystic kidney disease.

Authors:  Jeffrey Roix; Saurabh Saha
Journal:  BMC Nephrol       Date:  2013-10-25       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.